NLS Pharmaceutics (NLS Pharmaceutics) Total Assets : $1.85 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NLS Pharmaceutics Total Assets?

NLS Pharmaceutics's Total Assets for the quarter that ended in Dec. 2023 was $1.85 Mil.

During the past 12 months, NLS Pharmaceutics's average Total Assets Growth Rate was 188.40% per year. During the past 3 years, the average Total Assets Growth Rate was -5.30% per year. During the past 5 years, the average Total Assets Growth Rate was 23.20% per year.

During the past 7 years, NLS Pharmaceutics's highest 3-Year average Total Assets Growth Rate was 120.00%. The lowest was -11.60%. And the median was 14.30%.

Total Assets is connected with ROA %. NLS Pharmaceutics's annualized ROA % for the quarter that ended in Dec. 2023 was -442.94%. Total Assets is also linked to Revenue through Asset Turnover. NLS Pharmaceutics's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

NLS Pharmaceutics Total Assets Historical Data

The historical data trend for NLS Pharmaceutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NLS Pharmaceutics Total Assets Chart

NLS Pharmaceutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

0.70

1.21

5.77

9.28

1.85

NLS Pharmaceutics Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Assets	Get a 7-Day Free Trial								5.77	2.06	9.28	2.27	1.85

NLS Pharmaceutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

NLS Pharmaceutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	-8.834	+	10.68
	=	1.85

NLS Pharmaceutics's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	-8.834	+	10.68
	=	1.85

NLS Pharmaceutics (NAS:NLSP) Total Assets Explanation

Total Assets is connected with ROA %.

NLS Pharmaceutics's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-9.118	/	( (2.27	+	1.847)	/ 2 )
	=	-9.118	/	2.0585
	=	-442.94 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

NLS Pharmaceutics's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	0	/	( (2.27	+	1.847)	/ 2 )
=	0	/	2.0585
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

NLS Pharmaceutics Total Assets Related Terms

Thank you for viewing the detailed overview of NLS Pharmaceutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

NLS Pharmaceutics (NLS Pharmaceutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NLS Pharmaceutics Ltd (NAS:NLSP) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

The Circle 6, Zurich, CHE, 8058

Website

https://www.nlspharma.com

NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.